Floatz logo

Therapeutic Asset Ratings

637 results matching 1 filter

133,990 assets · 8,802 sponsors · 3,128 indications
Methodology v0.2
AssetSponsorPhaseRating
Tislelizumab
Rectal Neoplasms
Fudan UniversityP3BB (64)
S-1
Colorectal Neoplasm
Fudan UniversityP2BB (64)
Epirubicin
HER2-negative Breast Cancer
Fudan UniversityP2/3BB (64)
PROPOFOL
Colorectal Cancer
Fudan UniversityP4B (63)
Pyrotinib
Breast Cancer
Fudan UniversityP4B (63)
DALPICICLIB ISETIONATE
Triple Negative Breast Cancer (TNBC)
Fudan UniversityP3B (63)
Golidocitinib
Peripheral T Cell Lymphoma
Fudan UniversityP3B (63)
Letrozole
Metastatic Cancer
Fudan UniversityP3B (63)
Pyrotinib
Triple Negative Breast Cancer
Fudan UniversityP3B (63)
Rivoceranib
Immunotherapy
Fudan UniversityP3B (63)
Serplulimab
Rectal Cancer
Fudan UniversityP3B (63)
Tazemetostat
Peripheral T Cell Lymphoma
Fudan UniversityP3B (63)
(+)-VINCRISTINE
Triple Negative Breast Cancer
Fudan UniversityP2B (63)
LIDOCAINE
Colorectal Cancer
Fudan UniversityP4B (62)
Carboplatin
HER2-negative Breast Cancer
Fudan UniversityP3B (62)
Everolimus
Hormone Receptor Positive Tumor
Fudan UniversityP3B (62)
Tislelizumab
Kidney Cancer
Fudan UniversityP3B (62)
utd1
Triple-negative Breast Cancer
Fudan UniversityP3B (62)
Utidelone
TNBC
Fudan UniversityP3B (62)
Zoladex
HER2-positive Breast Cancer
Fudan UniversityP3B (62)
Carboplatin
Brain Metastases
Fudan UniversityP2B (62)
ETOPOSIDE
Ovarian Carcinoma
Fudan UniversityP2B (62)
Neratinib
Metastatic Breast Carcinoma
Fudan UniversityP2B (62)
Raltitrexed
Inoperable or Recurrent Rectal Cancer
Fudan UniversityP2B (62)
Inetetamab
HER2-positive Advanced Breast Cancer
Fudan UniversityP2/3B (62)
Showing 51 to 75 of 637 assets
PreviousPage 3 of 26Next